Top Story Today
One Pill Just Made Cholesterol Injections Optional
For ten years, the most powerful cholesterol drugs required injections, and roughly half of eligible patients simply refused the needle. That era ended this week when the FDA approved Merck's LIPFENDRA (enlicitide), the first oral PCSK9 inhibitor ever. The once-daily pill slashes LDL cholesterol by 56 to 59%, matching injectable-level potency at about $315 per month (roughly 30 to 40% cheaper than existing shots). AstraZeneca's competing oral PCSK9 program won't have outcomes data until 2029, giving Merck a massive first-mover window. Analysts project $5 billion or more in peak sales.
Why it matters: This approval could fundamentally reshape cholesterol management by converting millions of injection-averse patients into active PCSK9 users, expanding the entire market while giving Merck a critical revenue pillar as Keytruda faces biosimilar competition.
Read more →Deals and M&A
Lilly Drops $3.8 Billion on a Psychedelic Trip
Eli Lilly is acquiring AtaiBeckley for up to $3.8 billion, the largest Big Pharma bet ever on psychedelic medicine. The crown jewel is BPL-003, an intranasal 5-MeO-DMT spray with FDA Breakthrough designation for treatment-resistant depression that met all key endpoints in Phase 2b. The deal puts Lilly on a direct collision course with J&J's $2 billion Spravato franchise and signals psychedelics have officially graduated from fringe to pharma mainstream.
Read more →Italy's Government Just Bought Into U.S. Rare Disease
Italy's state lender pumped roughly one billion euros into family-owned Angelini Pharma to help it complete a $4.1 billion takeover of Catalyst Pharmaceuticals. It's an almost unprecedented move: a European government taking an equity stake to underwrite a cross-border pharma acquisition. Angelini, which lacked a meaningful U.S. prescription drug presence, now owns a profitable rare disease company generating nearly $600 million in annual sales.
Read more →The MyoKardia Crew Reunites With a $400 Million IPO
The team behind MyoKardia's $13.1 billion sale to Bristol Myers Squibb has reunited under the name Kardigan and just raised $400 million in one of 2026's largest biotech IPOs. Shares priced at the top of their range and popped 31% on day one. The company is targeting three cardiovascular conditions with zero approved therapies, backed by enough cash to operate into 2028.
Read more →Clinical and Regulatory
Takeda's $4 Billion Psoriasis Bet Just Paid Off
Takeda's zasocitinib ran the table in Phase 3 psoriasis trials, hitting both co-primary endpoints and all 44 ranked secondary measures. About one in three patients achieved total skin clearance, and the drug beat BMS's deucravacitinib by more than 2.5x on that measure in a head-to-head study. Peak sales projections now range from $3 billion to $6 billion.
Read more →Novartis's Kidney Drug Moves Closer to Full Approval
Novartis submitted two-year data for Fabhalta showing it slowed kidney function decline by 49% in IgA nephropathy and cut the risk of progressing to kidney failure by 43%. The data have been submitted to the FDA for conversion from accelerated to traditional approval and are under priority review. No other complement inhibitor is approved for the disease, giving Novartis a two-to-three-year window before competitors catch up.
Read more →GSK's Chronic Cough Drug Crashes in Phase 3
GSK killed a late-stage chronic cough program after the drug failed to hit key efficacy endpoints in Phase 3. The termination removes a potential first-in-class treatment for refractory chronic cough, a condition with almost no effective therapies, and deals a real blow to GSK's respiratory pipeline.
FierceBiotech →Tepezza's Six-Year Monopoly in Thyroid Eye Disease Is Over
The FDA approved Viridian's Lumvoa for thyroid eye disease, breaking the monopoly that Amgen's nearly $2 billion-a-year Tepezza has held since 2020. In trials, 70% of patients saw meaningful reduction in eye bulging, with potentially fewer hearing side effects than the incumbent. Viridian plans to price at parity with Tepezza, betting doctors will switch on clinical merit rather than cost.
Read more →Science, Tech, and Policy
Jennifer Doudna Built CRISPR Enzymes That Evolution Never Imagined
Doudna's team used an AI "inverse folding" model to design gene-editing enzymes from scratch: proteins that don't exist in nature but cut DNA in human cells as well as (or better than) the originals. Beyond the science, there's a business angle: sufficiently novel synthetic enzymes could sidestep the notoriously messy CRISPR patent landscape entirely.
Read more →The FDA Just Carpet-Bombed 25 Telehealth Firms Over Knockoff Ozempic
Twenty-five telehealth companies got FDA warning letters for marketing compounded semaglutide and tirzepatide with claims like "generic Wegovy," which is flatly false. The agency has now sent over 100 letters in under a year, citing 990 adverse event reports for compounded semaglutide alone. The crackdown is a structural gift to Novo Nordisk and Lilly as compounded supply dries up.
Read more →You Can Now Bet Real Money on FDA Approvals
Prediction market platform Kalshi launched more than a dozen contracts letting traders wager on Phase 3 trial results and FDA decisions. Contract prices reflect real-time crowd probabilities of drug approval. It's still early, and critics worry about insider trading risks, but the concept of market-priced pipeline probabilities could reshape how investors assess biotech risk.
Read more →